Participants 61 129 4
metastatic or recurrent squamous cell carcinoma of the head and neck
Participants 381 529 7
recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients, whose disease has progressed after platinum-containing therapy
Participants 611 635 5
43 centers; 124 patients
Participants 967 1089 5
A total of 121 patients were treated (61 afatinib, 60 cetuximab) and 68 crossed over to stage II (32 and 36 respectively).
